Glaukos Corporation · NYSE:GKOS
Glaukos — Investor Presentation (June 2016)
23 slides from Glaukos's investor presentation, Jun 6, 2016
Slide 1: Disclaimer
2 © 2016 Glaukos Corporation. DISCLAIMER All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe th
Slide 2: Aging Population Drives Glaucoma Prevalence
Reducing treatment IOP is the only proven for glaucoma 1 OAG 2015 2020 increase from 80mm in 2015 to 2015 Open-Angle Glaucoma 2020 All Glaucoma 4 © 2016 Glaukos Corporation. Aging Population Drives Glaucoma Prevalence US GLAUCOMA POPULATION1 (in millions) 5 4 Typically associated with elevated intra
Slide 3: How The Eye's Drainage System Works
© 2016 Glaukos Corporation. 5 How The Eye’s Drainage System Works Elevated IOP occurs when Secondary outflow pathway is aqueous humor outflow through the suprachoroidal space the trabecular meshwork and into Schlemm’s canal is reduced due to degeneration and obstruction
Slide 4: Conventional Glaucoma Treatment Options
dosing regimens; adverse Lack of long-term efficacy Medication may still be necessary post-treatment and payor © 2016 Glaukos Corporation. 6 Conventional Glaucoma Treatment Options Significant drawbacks limit effectiveness, create challenges for physicians & patients 01 02 03 Prescription Eye Drops
Slide 5: iStent vs. Conventional Surgery
© 2016 Glaukos Corporation. 7 iStent vs. Conventional Surgery Conventional Surgery
Slide 6: Our Solution Portfolio: Transformational Shift to Micro-Scale Injectable Therapy
8 © 2016 Glaukos Corporation. Our Solution Portfolio: Transformational Shift to Micro-Scale Injectable Therapy Precision solutions for complete range of glaucoma disease states & progression iStent® iStent Inject® iStent Supra® iDoseTM Used in combination Injectable 2-stent therapy Designed to acces
Slide 7: Comprehensive Clinical Results
Comprehensive Clinical Results © 2016 Glaukos Corporation. 9
Slide 8: Comprehensive Clinical Results: What We Are Discovering
10 © 2016 Glaukos Corporation. Comprehensive Clinical Results: What We Are Discovering 1. Recent published peer-reviewed clinical results show improvement over 2008 IDE pivotal trial –iStent + cataract surgery patients achieved IOP < 15 mm Hg at 3 years1 –65% of phakic/pseudophakic patients achieved
Slide 9: iStent Shown to Reduce IOP: US Pivotal Trial Results
Primary Endpoint Secondary Endpoint glaucoma device 11 © 2016 Glaukos Corporation. FDA Approved June 2012: iStent Shown to Reduce IOP US Pivotal Trial Results At 12 months, 85% IOP < 21 mm Hg w/o meds IOP > 20% w/o meds of iStent + cataract surgery group was medication free First prospective, Both g
Slide 10: Single iStent + Cataract Surgery Achieves < 15 mm Hg Through 3 Years
AT 36 MONTHS… CONSISTENT COHORT THROUGH 3 YEARS (n=39) 24 Preop Month 12 Month 24 Month 36 86% decision to implant based on eyes followed through 36 mean number of 12 mm Hg © 2016 Glaukos Corporation. Compelling Clinical Results: Single iStent + Cataract Surgery Achieves < 15 mm Hg Through 3 Years M
Slide 11: Long-term Efficacy of iStent + Cataract Surgery Shown in International Study
After mean follow-up of 16.5 16.3 16.1 16.1 15.9 Preop Month 1 Year 1 Year 2 Year 3 Year 4 Year 5 Final 13 mm Hg © 2016 Glaukos Corporation. Compelling Clinical Results: Long-term Efficacy of iStent + Cataract Surgery Shown in International Study + CATARACT SURGERY 2019. 4Mean IOP 54 months, 42% of
Slide 12: International Study Shows IOP-Lowering Capability of 1, 2 and 3 iStents
Demonstrates potential Medications 14.1 14 groups with preoperative in standalone Mean preop medicated Mean preop IOP after Month 18 mean IOP 14 mm Hg © 2016 Glaukos Corporation. Compelling Clinical Results: International Study Shows IOP-Lowering Capability of 1, 2 and 3 iStents Mean IOP at 18 Month
Slide 13: Proportional Analyses of IOP at 12 Months
Demonstrates potential Glaucoma Medications % of eyes 85% 1 Stent Group (n=37) 2 Stent Group (n=41) 3 Stent Group (n=38) groups with preoperative in standalone mm Hg continue for 5 years 15 © 2016 Glaukos Corporation. Compelling Clinical Results: International Study Shows IOP-Lowering Capability of
Slide 14: International Study of Dual Physiologic Outflow in Failed Trab Patients
97% achieved > 20% 26.4 13.6 13.7 13.3 13.6 13.4 12.9 12.5 12.2 combining Schlemm’s canal and suprachoroidal 11 Screening Baseline Day 1 Week 1 Month 1 Month 6 Month 12 Month 18 Month 24 Month 30 Month 36 16 Mean IOP (mm Hg) © 2016 Glaukos Corporation. Compelling Combination Clinical Results: Intern
Slide 15: Clinical Research Program Statistics
18 Prospective clinical trials currently underway Articles published in journals 17 © 2016 Glaukos Corporation. Clinical Research Program Statistics 40 peer-reviewed
Slide 16: Global Commercial Operations
Global Commercial Operations © 2016 Glaukos Corporation. 18
Slide 17: Seizing First Mover Opportunity in Targeted Markets: Commercial Execution Highlights
Delivered strong revenue and surgeon Direct sales teams established in Established seasoned ophthalmic sales Medicare or private insurance served by ophthalmic distributors Investing in multiple programs to approximately $500 higher for iStent + physicians and patients on iStent alone 19 © 2016 Glau
Slide 18: Q1 2016 Financial & Operational Performance
(in millions) $25 $23.1 $20 in Q1 2015 in Q1 2016 $15 57% year-over-year growth in net sales 20 © 2016 Glaukos Corporation. Q1 2016 Financial & Operational Performance: Growth Reflects iStent Adoption Trends Avg. Number of US Sales Reps TOTAL NET SALES 41 49 20% year-over-year growth in domestic sal
Slide 19: Future Potential MIGS Market Participants
Inject 21 © 2016 Glaukos Corporation. Future Potential MIGS Market Participants ALCON/TRANSCEND CYPASS 6.35mm suprachoroidal device for implantation into supraciliary space using guidewire delivery (actual) IVANTIS HYDRUS 8mm nitinol scaffolding device implanted into Schlemm’s canal (image) iStent i
Slide 20: Financial Summary
2013 2014 2015 2016 2015 2016 22 © 2016 Glaukos Corporation. Financial Summary NET SALES GROSS MARGIN (IN MILLIONS) Strong net sales growth driven by increased iStent utilization across an expanding customer base Favorable gross margin reflects efficient manufacturing and cost structure Continued in
Slide 21: Growth Strategies: Establishing MIGS as OAG Standard of Care
23 © 2016 Glaukos Corporation. Growth Strategies: Establishing MIGS as OAG Standard of Care 01 02 03 04 Increase US iStent Secure FDA approvals Develop, secure Extend global reach of adoption with seasoned with expanded regulatory approval for MIGS-based platform sales force, broad indications for i
Slide 22: © 2016 Glaukos Corporation. 24
© 2016 Glaukos Corporation. 24
Slide 23: Glaukos MIGS